The Sensitivity of Diffuse Large B-Cell Lymphoma Cell Lines to Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated by BCL-2 Family Protein Activity

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Thompson, Ryan C ^a   Vardinogiannis, Iosif ^a   Gilmore, Thomas D ^a  

^a Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; HISTONE DEACETYLASE INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; TRICHOSTATIN A; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; EMBRYO; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOMA CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84877117327     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062822     Document Type: Article

References (70)

1. Hunt KE, Reichard KK, (2008) Diffuse large B-cell lymphoma. Arch Pathol Lab Med 10: 118-124.
2. Lenz G, Wright G, Dave SS, Xiao W, Powell J, et al. (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359: 2313-2323.
3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947.
4. Leonard JP, Martin P, Barrientos J, Elstrom R, (2008) Targeted treatment and new agents in diffuse large B-cell lymphoma. Semin Hematol 45: 11-16.
5. Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
6. Cotto M, Cabanillas F, Tirado M, Garcia MV, Pacheco E, (2010) Epigenetic therapy of lymphoma using histone deacetylase inhibitors. Clin Transl Oncol 12: 401-409.
7. Wiegmans AP, Alsop AE, Bots M, Cluse LA, Williams SP, et al. (2011) Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737. Cancer Res 71: 3603-3615.
8. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, et al. (2005) Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33: 53-61.
9. Bodo J, Sedlak J, Maciejewski JP, Almasan A, Hsi ED, (2011) HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. Apoptosis 16: 914-923.
10. Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, et al. (2008) Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 19: 964-969.
11. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, et al. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24: 166-173.
12. Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, et al. (2010) The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 115: 4478-4487.
13. Chen ZJ, Zhang B, Pan SH, Zhao HM, Zhang Y, et al. (2011) Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells. Zhonghua Zhong Liu Za Zhi 33: 891-895.
14. Strasser A, Cory S, Adams JM, (2011) Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 30: 3667-3683.
15. Shamas-Din A, Brahmbhatt H, Leber B, Andrews DW, (2011) BH3-only proteins: orchestrators of apoptosis. Biochim Biophys Acta 1813: 508-520.
16. Walensky LD, Gavathiotis E, (2011) BAX unleashed: the biochemical transformation of an inactive cytosolic monomer into a toxic mitochondrial pore. Trends Biochem Sci 36: 642-652.
17. Faber AC, Li D, Song Y, Liang MC, Yeap BY, et al. (2009) Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 106: 19503-19508.
18. Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, et al. (2011) BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 1: 352-365.
19. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, et al. (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967-969.
20. Sturm I, Stephan C, Gillissen B, Siebert R, Janz M, et al. (2006) Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ 13: 619-627.
21. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R, Climent J, et al. (2007) Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 109: 271-280.
22. Brimmell M, Mendiola R, Mangion J, Packham G, (1998) BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 16: 1803-1812.
23. Yarkoni S, Lishner M, Tangi I, Nagler A, Lorberboum-Galski H, (1996) B-cell non-Hodgkin's lymphoma: evidence for the t (14;18) translocation in all hematopoietic cell lineages. J Natl Cancer Inst 88: 973-979.
24. Youle RJ, Strasser A, (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59.
25. Jing H, Kase J, Dörr JR, Milanovic M, Lenze D, et al. (2011) Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev 25: 2137-2146.
26. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
27. Chen S, Dai Y, Pei XY, Grant S, (2009) Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol 29: 6149-6169.
28. Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, et al. (2011) Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood 118: 1329-1339.
29. Allaman-Pillet N, Oberson A, Munier F, Schorderet DF (2011) The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells. Ophthalmic Genet, in press.
30. Debien E, Hervouet E, Gautier F, Juin P, Vallette FM, et al. (2011) ABT-737 and/or folate reverse the PDGF-induced alterations in the mitochondrial apoptotic pathway in low-grade glioma patients. Clin Epigenetics 2: 369-381.
31. Fang H, Harned TM, Kalous O, Maldonado V, DeClerck YA, et al. (2011) Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clin Cancer Res 17: 7093-7104.
32. Risberg K, Fodstad O, Andersson Y, (2011) Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma. PLoS ONE 6: e24012.
33. Ishitsuka K, Kunami N, Katsuya H, Nogami R, Ishikawa C, et al. (2012) Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Cancer Lett 317: 218-225.
34. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, et al. (2007) Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117: 112-121.
35. Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, et al. (2008) The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112: 2906-2916.
36. Yeo AT, Porco JA Jr, Gilmore TD, (2012) Bcl-XL, but not Bcl-2, can protect human B-lymphoma cell lines from parthenolide-induced apoptosis. Cancer Lett 318: 53-60.
37. Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Petru E, et al. (2010) Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer 9: 49.
38. Pitts TM, Morrow M, Kaufman SA, Tentler JJ, Eckhardt SG, (2009) Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther 8: 342-349.
39. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, et al. (2005) Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 102: 16090-16095.
40. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, et al. (2003) Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278: 12579-12589.
41. Dalgard CL, Van Quill KR, O'Brien JM, (2008) Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin Cancer Res 14: 3113-3123.
42. Morales JC, Ruiz-Magana MJ, Carranza D, Ortiz-Ferron G, Ruiz-Ruiz C, (2010) HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis. Cancer Lett 297: 91-100.
43. Fitzgerald DJ, Moskatel E, Ben-Josef G, Traini R, Tendler T, et al. (2011) Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. Leuk Lymphoma 52Suppl 2: 79-81.
44. Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, et al. (2009) Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 113: 1982-1991.
45. Sevilla L, Zaldumbide A, Pognonec P, Boulukos KE, (2001) Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFkappaB, STAT and AP1 transcription factor families. Histol Histopathol 16: 595-601.
46. Chen C, Edelstein LC, Gélinas C, (2000) The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL. Mol Cell Biol 20: 2687-95.
47. Bhattacharya S, Ray RM, Johnson LR, (2005) STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J 392: 335-344.
48. Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, et al. (2008) Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111: 1515-1523.
49. Gupta M, Han JJ, Stenson M, Wellik L, Witzig TE, (2011) Regulation of STAT3 by histone deaceylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 26: 1356-1364.
50. Tsutsui M, Yasuda H, Suto H, Imai H, Isobe Y, et al. (2010) Frequent STAT activiation is associated with Mcl-1 expression in NK-cell lymphoma. Int J Lab Hematol 32: 419-426.
51. Wenzel SS, Grau M, Mavis C, Hailfinger S, Wolf A, et al. (2012) MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia [epub ahead of print].
52. Davis RE, Brown KD, Siebenlist U, Staudt LM, (2001) Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194: 1861-1874.
53. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, et al. (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100: 9991-9996.
54. Chin M, Herscovitch M, Zhang N, Waxman DJ, Gilmore TD, (2009) Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profile. Oncogene 28: 2100-2111.
55. Alizadeh AA, Elsen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
56. Chen LF, Fischle W, Verdin E, Greene WC, (2001) Duration of nuclear NF-κB action regulated by reversible acetylation. Science 293: 1653-1657.
57. Chen LF, Mu Y, Greene WC, (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J 21: 6539-6548.
58. Nusinzon I, Horvath CM, (2003) Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci USA 100: 14742-14747.
59. Yuan ZL, Guan YJ, Chatterjee D, Chin YE, (2005) Stat3 dimerization by reversible acetylation of a single lysine residue. Science 307: 269-273.
60. Fantin VR, Loboda A, Paweletz CP, Hendrickson RC, Pierce JW, (2008) Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res 68: 3785-3794.
61. Yecies D, Carlson NE, Deng J, Letai A, (2010) Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 BFL-1. Blood 115: 3304-3313.
62. Chen S, Dai Y, Harada H, Dent P, Grant S, (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 15: 782-791.
63. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, et al. (2006) The BD3 mimetic ABT-737 targets selective BCL-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399.
64. Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, et al. (2007) Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clin Cancer Res 13: 2226-2235.
65. Thompson RC, Herscovitch M, Zhao I, Ford TJ, Gilmore TD, (2001) NF-κB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. J Biol Chem 286: 1675-1682.
66. Garbati MR, Thompson RC, Haery L, Gilmore TD, (2011) A rearranged EP300 gene in the human B-cell lymphoma cell line RC-K8 encodes a disabled transcriptional co-activator that contributes to cell growth and oncogenicity. Cancer Lett 302: 76-83.
67. Longe HO, Romesser PB, Rankin AM, Faller DV, Eller MS, et al. (2009) Telomer homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential. Int J Cancer 124: 473-482.
68. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, et al. (2011) Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471: 189-196.
69. Gilmore TD, Jean-Jacques J, Richards R, Cormier C, Kim J, Kalaitzidis D, (2003) Stable expression of the avian retroviral oncoprotein v-Rel in avian, mouse, and dog cell lines. Virology 316: 9-16.
70. Ribble D, Goldstein NB, Norris DA, Shellman YG, (2005) A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 5: 12.